Altivera

Altivera is a clinical-stage biotechnology company dedicated to developing transformative therapies for patients with respiratory diseases, with a primary focus on Cystic Fibrosis (CF). The company's lead program, ALV-101, is a novel small molecule designed to modulate the CFTR protein, aiming to address the underlying cause of the disease in a broad range of patients. By leveraging deep expertise in ion channel pharmacology and respiratory medicine, Altivera seeks to provide next-generation treatments that improve lung function and quality of life. The company is currently advancing its pipeline through early-stage clinical trials to validate the safety and efficacy of its therapeutic candidates.